RxDoctor Payments Data

Kristina Reilly, APRN

Family · Clarksville, TNNPI 1043992449

Payments from drug & device makers

$1,289in general payments, 2019–2025

Across 60 payments — averaging $21.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$346
  • Novo Nordisk$248
  • Pacira Pharmaceuticals Incorporated$125
  • Lilly USA, LLC$103
  • AbbVie$97
  • Medtronic$89
  • plus $281 from 9 others

What the payments were for

  • Food & beverage$1,289100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,289 in reported general payments places this provider in the 65th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$41,510
Medicare patients
204
Services billed
855

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$94,714
TrulicityDulaglutide29$28,258
JardianceEmpagliflozin12$20,218
XareltoRivaroxaban16$18,273
JanuviaSitagliptin Phosphate18$16,723
EliquisApixaban17$16,054
RybelsusSemaglutide11$13,614
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$5,510
Tresiba Flextouch U-100Insulin Degludec11$5,330
Fluticasone Propionate HfaFluticasone Propionate12$4,283
LantusInsulin Glargine,hum.Rec.Anlog16$3,316
SymbicortBudesonide/Formoterol Fumarate11$2,683
Novolog FlexpenInsulin Aspart14$2,440
Albuterol Sulfate HfaAlbuterol Sulfate120$2,358
Duloxetine Hcl51$2,254

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$248$108,32784 claims
Lilly USA, LLCTrulicity$103$28,25829 claims
MerckJanuvia$55$16,72318 claims
PfizerEliquis$15$16,05417 claims
AstraZenecaSymbicort$346$2,68311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,706 family providers in Tennessee.

Other family in Clarksville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →